Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

233 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Epidermal growth factor receptor mutations in lung cancer.
Sharma SV, Bell DW, Settleman J, Haber DA. Sharma SV, et al. Among authors: settleman j. Nat Rev Cancer. 2007 Mar;7(3):169-81. doi: 10.1038/nrc2088. Nat Rev Cancer. 2007. PMID: 17318210 Review.
Cancer: Bet on drug resistance.
Settleman J. Settleman J. Nature. 2016 Jan 21;529(7586):289-90. doi: 10.1038/nature16863. Epub 2016 Jan 6. Nature. 2016. PMID: 26735017 No abstract available.
Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism.
Perera RM, Stoykova S, Nicolay BN, Ross KN, Fitamant J, Boukhali M, Lengrand J, Deshpande V, Selig MK, Ferrone CR, Settleman J, Stephanopoulos G, Dyson NJ, Zoncu R, Ramaswamy S, Haas W, Bardeesy N. Perera RM, et al. Among authors: settleman j. Nature. 2015 Aug 20;524(7565):361-5. doi: 10.1038/nature14587. Epub 2015 Jul 13. Nature. 2015. PMID: 26168401 Free PMC article.
Cancer: drivers and passengers.
Haber DA, Settleman J. Haber DA, et al. Among authors: settleman j. Nature. 2007 Mar 8;446(7132):145-6. doi: 10.1038/446145a. Nature. 2007. PMID: 17344839 No abstract available.
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.
Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, Salido M, Gallen M, Marsters S, Tsai SP, Minoche A, Seshagiri S, Serrano S, Himmelbauer H, Bellmunt J, Rovira A, Settleman J, Bosch F, Albanell J. Montagut C, et al. Among authors: settleman j. Nat Med. 2012 Jan 22;18(2):221-3. doi: 10.1038/nm.2609. Nat Med. 2012. PMID: 22270724
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.
Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J. Wilson TR, et al. Among authors: settleman j. Nature. 2012 Jul 26;487(7408):505-9. doi: 10.1038/nature11249. Nature. 2012. PMID: 22763448 Free PMC article.
A therapeutic opportunity in melanoma: ErbB4 makes a mark on skin.
Settleman J. Settleman J. Cancer Cell. 2009 Oct 6;16(4):278-9. doi: 10.1016/j.ccr.2009.09.013. Cancer Cell. 2009. PMID: 19800573
The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation.
Raha D, Wilson TR, Peng J, Peterson D, Yue P, Evangelista M, Wilson C, Merchant M, Settleman J. Raha D, et al. Among authors: settleman j. Cancer Res. 2014 Jul 1;74(13):3579-90. doi: 10.1158/0008-5472.CAN-13-3456. Epub 2014 May 8. Cancer Res. 2014. PMID: 24812274
Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations.
Galimberti F, Busch AM, Chinyengetere F, Ma T, Sekula D, Memoli VA, Dragnev KH, Liu F, Johnson KC, Guo Y, Freemantle SJ, Andrew AS, Greninger P, Robbins DJ, Settleman J, Benes C, Dmitrovsky E. Galimberti F, et al. Among authors: settleman j. Int J Oncol. 2012 Nov;41(5):1751-61. doi: 10.3892/ijo.2012.1599. Epub 2012 Aug 22. Int J Oncol. 2012. PMID: 22923130 Free PMC article.
AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs.
Wilson C, Ye X, Pham T, Lin E, Chan S, McNamara E, Neve RM, Belmont L, Koeppen H, Yauch RL, Ashkenazi A, Settleman J. Wilson C, et al. Among authors: settleman j. Cancer Res. 2014 Oct 15;74(20):5878-90. doi: 10.1158/0008-5472.CAN-14-1009. Epub 2014 Aug 14. Cancer Res. 2014. PMID: 25125659
233 results
Jump to page